S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
WARNING to all American Investors (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
WARNING to all American Investors (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
WARNING to all American Investors (Ad)
Oregon Democratic Party to send federal officials a $500,000 donation from former FTX executive
North Dakota tribe buys idle oil pipeline from Enbridge
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
WARNING to all American Investors (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
WARNING to all American Investors (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
WARNING to all American Investors (Ad)
Oregon Democratic Party to send federal officials a $500,000 donation from former FTX executive
North Dakota tribe buys idle oil pipeline from Enbridge
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
WARNING to all American Investors (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
WARNING to all American Investors (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
WARNING to all American Investors (Ad)
Oregon Democratic Party to send federal officials a $500,000 donation from former FTX executive
North Dakota tribe buys idle oil pipeline from Enbridge
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
WARNING to all American Investors (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
WARNING to all American Investors (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
WARNING to all American Investors (Ad)
Oregon Democratic Party to send federal officials a $500,000 donation from former FTX executive
North Dakota tribe buys idle oil pipeline from Enbridge
NYSE:RMD

ResMed (RMD) Competitors

$213.53
-1.40 (-0.65%)
(As of 06/9/2023 ET)
Compare
Today's Range
$212.62
$215.40
50-Day Range
$209.98
$240.96
52-Week Range
$194.30
$247.65
Volume
511,996 shs
Average Volume
694,310 shs
Market Capitalization
$31.37 billion
P/E Ratio
36.38
Dividend Yield
0.82%
Price Target
$263.43

RMD vs. BAX, PODD, DXCM, TFX, BSX, BDX, SYK, WST, PEN, and SWAV

Should you be buying ResMed stock or one of its competitors? The main competitors of ResMed include Baxter International (BAX), Insulet (PODD), DexCom (DXCM), Teleflex (TFX), Boston Scientific (BSX), Becton, Dickinson and (BDX), Stryker (SYK), West Pharmaceutical Services (WST), Penumbra (PEN), and Shockwave Medical (SWAV). These companies are all part of the "surgical & medical instruments" industry.

ResMed vs.

Baxter International (NYSE:BAX) and ResMed (NYSE:RMD) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk.

ResMed has a net margin of 21.49% compared to Baxter International's net margin of -16.34%. ResMed's return on equity of 25.82% beat Baxter International's return on equity.

Company Net Margins Return on Equity Return on Assets
Baxter International -16.34% 24.29% 5.49%
ResMed 21.49% 25.82% 15.78%

Baxter International currently has a consensus target price of $52.38, suggesting a potential upside of 24.79%. ResMed has a consensus target price of $263.43, suggesting a potential upside of 23.37%. Given Baxter International's higher probable upside, analysts plainly believe Baxter International is more favorable than ResMed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Baxter International
1 Sell rating(s)
9 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.21
ResMed
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.78

Baxter International has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, ResMed has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500.

Baxter International received 324 more outperform votes than ResMed when rated by MarketBeat users. Likewise, 67.10% of users gave Baxter International an outperform vote while only 53.00% of users gave ResMed an outperform vote.

CompanyUnderperformOutperform
Baxter InternationalOutperform Votes
722
67.10%
Underperform Votes
354
32.90%
ResMedOutperform Votes
398
53.00%
Underperform Votes
353
47.00%

In the previous week, ResMed had 5 more articles in the media than Baxter International. MarketBeat recorded 8 mentions for ResMed and 3 mentions for Baxter International. Baxter International's average media sentiment score of 0.39 beat ResMed's score of 0.07 indicating that Baxter International is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Baxter International
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ResMed
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

84.8% of Baxter International shares are held by institutional investors. Comparatively, 64.7% of ResMed shares are held by institutional investors. 0.2% of Baxter International shares are held by insiders. Comparatively, 1.4% of ResMed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ResMed has lower revenue, but higher earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Baxter International$15.11 billion1.40-$2.43 billion-$4.88-8.60
ResMed$3.58 billion8.77$779.44 million$5.8736.38

Baxter International pays an annual dividend of $1.16 per share and has a dividend yield of 2.8%. ResMed pays an annual dividend of $1.76 per share and has a dividend yield of 0.8%. Baxter International pays out -23.8% of its earnings in the form of a dividend. ResMed pays out 30.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Baxter International has increased its dividend for 7 consecutive years and ResMed has increased its dividend for 2 consecutive years. Baxter International is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

ResMed beats Baxter International on 11 of the 21 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RMD vs. The Competition

MetricResMedSurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$31.37B$3.69B$4.58B$14.99B
Dividend Yield0.82%2.76%2.26%3.85%
P/E Ratio36.3829.6892.9519.54
Price / Sales8.7756.593,376.909.24
Price / Cash30.1069.0194.0824.62
Price / Book9.304.624.717.33
Net Income$779.44M$61.59M$117.47M$900.99M
7 Day Performance-3.22%0.54%0.81%1.75%
1 Month Performance-8.55%-0.97%1.01%3.87%
1 Year Performance2.41%-3.61%19.11%-2.53%

ResMed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BAX
Baxter International
2.4154 of 5 stars
$40.95
-1.7%
$52.38
+27.9%
-41.7%$20.71B$15.11B-8.3960,000
PODD
Insulet
2.1466 of 5 stars
$285.56
+0.5%
$330.00
+15.6%
+29.1%$19.90B$1.31B240.202,600Insider Selling
DXCM
DexCom
1.933 of 5 stars
$125.38
+0.6%
$126.81
+1.1%
+67.8%$48.60B$3.02B179.127,600
TFX
Teleflex
2.3093 of 5 stars
$235.98
-1.9%
$273.38
+15.9%
-12.8%$11.07B$2.86B30.7715,500
BSX
Boston Scientific
2.574 of 5 stars
$50.67
-1.4%
$54.00
+6.6%
+35.1%$70.94B$12.68B85.8845,000
BDX
Becton, Dickinson and
2.5061 of 5 stars
$250.46
-1.4%
$276.60
+10.4%
+1.3%$71.13B$18.81B46.9977,000
SYK
Stryker
2.8799 of 5 stars
$276.55
-0.5%
$302.00
+9.2%
+28.2%$104.77B$18.45B40.2551,000
WST
West Pharmaceutical Services
2.4239 of 5 stars
$346.19
+0.8%
$313.00
-9.6%
+14.4%$25.70B$2.89B47.5513,550
PEN
Penumbra
1.9667 of 5 stars
$322.50
+0.2%
$296.33
-8.1%
+141.7%$12.34B$847.13M2,015.753,900Analyst Revision
SWAV
Shockwave Medical
2.4478 of 5 stars
$290.59
0.0%
$273.78
-5.8%
+56.9%$10.64B$489.73M45.831,001Positive News

Related Companies and Tools

This page (NYSE:RMD) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -